ABLEDOCS
6.4.2021 14:03:02 CEST | Business Wire | Pressemeddelelse
AbleDocs Inc. , globalt førende udbyder af tilgængelige PDF-produkter og -services, og Diversa Docs ApS , anerkendte eksperter inden for PDF- og Web-tilgængelighedsydelser, annoncerer, at de går sammen for at blive førende i Skandinavien inden for PDF-tilgængelighedsprodukter og -services.
Med en allerede mangeårig historik for samarbejde glæder begge virksomheders grundlæggere og lederteam til at udnytte hinandens muligheder for at tilbyde større fordele til eksisterende og nye kunder.
”Diversa Docs er bredt anerkendt for deres ekspertise inden for levering af PDF/UA-kompatible og tilgængelige PDF-filer, og denne erhvervelse giver vores kombinerede kundebase mulighed for at drage fordel af oplevelsen og omfanget af vores produkter og tjenester i hele Skandinavien,” siger AbleDocs 'Præsident (GLOBAL), Adam Spencer .
”Med deres fantastiske hold og fokuserede tilgang på slutbrugeren er de den ideelle partner for AbleDocs. Med vores samlede indsats kan sammen vi drive udbredelsen af næste generations PDF-tilgængelighedstjenester og -løsninger, ”siger Vice President (SCANDINAVIA), Jens Bjerre Kirkegaard .
”Tilgængelighed har altid appelleret til mig, fordi det kombinerer et teknisk felt med et humanistisk område,” siger administrerende direktør for Diversa Docs, Asbjørn Fangel-Hansen . ”Efter at have arbejdet i 12 år i den danske offentlige sektor inden for tilgængelighed og senest som ejer af en af de førende virksomheder inden for tilgængelighed i Danmark, er jeg meget beæret over at blive en del af en af de absolut førende globale aktører, når det kommer til tilgængelige dokumenter, ”tilføjer Fangel-Hansen.
Kombinationen af AbleDocs og Diversa Docs vil udvide den globale tilstedeværelse af AbleDocs med produkter, services, udvikling af løsninger og uddannelse tilpasset til lokale forhold på 49 sprog for at sikre, at kunderne får de bedst mulige tilbud.
Om Diversa Docs
Diversa Docs ApS blev grundlagt af Lars Holm-Sørensen og Asbjørn Fangel-Hansen i 2019 som søsterselskab til Diversa ApS. Siden da har virksomheden udviklet sig til at være en af de førende i Danmark med hensyn til dokumenttilgængelighed og området generelt.
Om AbleDocs Inc.
AbleDocs blev grundlagt i 2019 som et konglomerat af udbydere af PDF-tilgængelighedstjenester og er vokset til at have aktiviteter i Canada, Danmark, Tyskland, Schweiz og USA. Grundlæggerne har mere end 150 års kombineret erfaring med tilgængelige dokumenter i og har siden udvidet sine tilbud til også at inkludere en helt ny tilgang til dokumenttilgængelighedsstrategier og løsninger til tilgængelige dokument produceret i store mængder samt test af tilgængelige dokumenter.
AbleDocs er det eneste firma i verden, der garanterer, at hver fil, de producerer, overholder gældende lovgivning for tilgængelighed og bakker det op med en garanti på $ 10.000.000.
Aktuelle produkter og services fra AbleDocs inkluderer ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord og axesPDF.
For mere information, besøg https://www.abledocs.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210406005231/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum